Purpose: To compare the diagnostic performance of MRI using the PI-RR scoring system and PSMA-PET/CT in detecting prostate cancer (PCa) local recurrence after radical prostatectomy (RP), and to identify clinical and imaging variables independently associated with recurrence. Materials and Methods: This retrospective, multicenter study evaluated 119 patients with suspected PCa recurrence who underwent both MRI and PSMA-PET/CT; MRI was performed within a time window ranging from up to 3 months before to a maximum of 1 month after the PET/CT examination; the time range was defined within MDTs. Both radiologists and nuclear medicine physicians were blinded to clinical and opposite imaging data during image interpretation. Exclusion criteria included insufficient follow-up, recent pelvic radiation (within 6 months), and history of hormone therapy. Reference standard was defined using histopathologic findings, follow-up imaging, or clinical response to treatment. Sensitivity, specificity, PPV, NPV, and accuracy were calculated. The Cohen’s kappa coefficient was used to determine inter-reader agreement. Univariable and multivariable logistic regression analyses were performed. Results: MRI, considering a PI-RR ≥ 3, detected recurrence in 69 patients versus 48 with PSMA-PET/CT ( p = 0.006). MRI showed significantly higher sensitivity (86%, 95% CI 75–92% vs. 71%, 95% CI 59–80%; p = 0.03) and a trend toward higher specificity (78%, 95% CI 65–87% vs. 52%, 95% CI 39–65%; p = 0.06), PPV (74% vs. 51%), NPV (89% vs. 73%). Overall accuracy was also superior for MRI (81%, 95% CI 74–87% vs. 63%, 95% CI 54–71%). ROC analysis confirmed a higher AUC for MRI (0.87, 95% CI 0.80–0.93) compared with PSMA-PET/CT (0.62, 95% CI 0.52–0.72; ΔAUC = 0.25, p < 0.001). Multivariable analysis showed that only age ( p = 0.002) and PI-RR score ≥ 3 ( p = 0.001) were independently correlated with recurrence. Postoperative risk grouping was correlated only at univariable analysis. Among the 119 included patients, histopathologic confirmation was available in 3% ( n = 4), treatment response (either biochemical or imaging based) in 31% (n = 37), follow-up with imaging in 33% ( n = 39), and clinical-laboratory follow-up in 33% ( n = 39).The median follow-up was 12 months (IQR, 9–18). The effective recurrence rate was 58%. Conclusions: MRI demonstrated strong diagnostic performance in detecting prostate cancer local recurrence. These findings suggest that MRI may be particularly useful for rule out local recurrence in low-risk patients, while PET/CT could be more appropriate for rule in, both local and distant in higher-risk patients. However, this proposed risk-adapted imaging strategy should be considered hypothesis-generating and warrants further validation through prespecified risk-stratified analyses. Limitations include the retrospective design, the composite reference standard, and the relatively high recurrence prevalence, which may have influenced predictive values.